언어 선택

Coagulation Factor III

Coagulation Factor III 분자 정보

영어 이름	Tissue factor	시판 약물 수	1
임상 약물 수	7	표적 별명	Coagulation Factor III (Thromboplastin， Tissue Factor)，Thromboplastin，Coagulation Factor III， Tissue Factor，TFA，F3，TF，CD142 Antigen，CD142，Coagulation Factor III，Tissue Factor
최고 연구 개발 단계	Approved

영어 이름	Tissue factor
표적 별명	Coagulation Factor III (Thromboplastin， Tissue Factor)，Thromboplastin，Coagulation Factor III， Tissue Factor，TFA，F3，TF，CD142 Antigen，CD142，Coagulation Factor III，Tissue Factor
시판 약물 수	1
임상 약물 수	7
최고 연구 개발 단계	Approved

Coagulation Factor III 제품 목록

속성
Protein (7)
제품 라이브러리
온라인 (7)
종
Human (4)Mouse (1)Cynomolgus (1)Canine (1)
태그
His Tag (4)Fc Tag (1)His Tag & Avi Tag (1)Fc Tag & Avi Tag (1)
마커
Unconjugated (5)Biotin-labeled (2)

제품 번호	종	발현 시스템	제품 설명
HOT TF3-H5253	Human	HEK293	Human Coagulation Factor III / Tissue Factor Protein, Fc Tag (active enzyme, MALS verified)
HOT TF3-H52H5	Human	HEK293	Human Coagulation Factor III / Tissue Factor Protein, His Tag, low endotoxin (active enzyme, MALS verified)
HOT TF3-M52H3	Mouse	HEK293	Mouse Coagulation Factor III / Tissue Factor Protein, His Tag (MALS verified)
TF3-H82E3	Human	HEK293	Biotinylated Human Coagulation Factor III / Tissue Factor Protein, His,Avitag™ (MALS & SPR verified)
TF3-H82F3	Human	HEK293	Biotinylated Human Coagulation Factor III / Tissue Factor Protein, Fc,Avitag™ (MALS & SPR verified)
TF3-C52H3	Cynomolgus	HEK293	Cynomolgus Coagulation Factor III / Tissue Factor Protein, His Tag (active enzyme, MALS verified)
TF3-C52H4	Canine	HEK293	Canine Coagulation Factor III / Tissue Factor Protein, His Tag (MALS verified)

총 수량7

Coagulation Factor III분자 배경

Full-length tissue factor (TF) is a transmembrane receptor and cofactor for factor (F)VII/FVIIa. In addition to full-length TF, an alternative spliced (as) form of TF can be generated that lacks the transmembrane domain and is released fromcells. In contrast to TF, asTF has low procoagulant activity because it lacks the transmembrane domain. Tissue factor is expressed by cells around blood vessels, such as adventitial fibroblasts, and body surfaces, such as epithelial cells, and plays a critical role in hemostasis. TF also contributes to various forms of thrombosis. Many cancers, particularly adenocarcinomas, express high levels of TF. A high level of tumor TF expression is associated with poor prognosis in many types of cancers, including breast, prostate, colorectal, and pancreatic cancer.

Coagulation Factor III분자 별명

Coagulation Factor III,Tissue Factor,TF,F3,CD142

임상 약물 정보

영어 이름	연구 코드	연구 개발 단계	회사	적응증	임상 시험
Anpocogin	AB-201	Phase 3 Clinical	Dendreon Uk Ltd	Coronavirus Disease 2019 (COVID-19)	상세
XNW-28012	XNW-28012; XNW28012	Phase 3 Clinical	Shanghai Cigna Biotech Pharmaceutical Co Ltd	Ovarian Neoplasms; Pancreatic Neoplasms; Solid tumours; Uterine Cervical Neoplasms	상세
MRG-004A	MRG004A	Phase 3 Clinical	Shanghai Miracogen Inc	Pancreatic Neoplasms; Solid tumours	상세
XB-002	XB-002; ICON-2	Phase 1 Clinical	Iconic Therapeutics Inc	Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Urogenital Neoplasms; Uterine Cervical Neoplasms	상세
XB-371	XB-371; XB371	Phase 1 Clinical	Catalent Inc, Exelixis Inc	Neoplasms; Solid tumours	상세
STRO-004	STRO-004	Phase 1 Clinical	Sutro Biopharma Inc	Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Uterine Cervical Neoplasms	상세
AMT-754	ADCE-T02; AMT-754	Phase 1 Clinical	Multitude Therapeutics Inc	Solid tumours	상세

시판 약물 정보

영어 이름	연구 코드	연구 개발 단계	회사	가장 빠른 브랜드 이름	가장 빠른 승인 국가	가장 빠른 적응증	가장 빠른 승인 회사	가장 빠른 승인 날짜	적응증	임상 시험
Tisotumab vedotin	TF-011-MMAE	Approved	Genmab A/S	HuMax-TF, TIVDAK	United States	Uterine Cervical Neoplasms	Seagen Inc	2021-09-20	Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms	상세